Imatinib Grindeks

Imatinib, the active ingredient in Imatinib Grindeks, is a tyrosine kinase inhibitor presented as a oral tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib is a targeted therapy that inhibits specific tyrosine kinases involved in certain hematologic and solid tumours.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves durable hematologic and cytogenetic responses. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission by blocking BCR‑ABL signaling in malignant lymphoblasts. - Gastrointestinal stromal tumor (GIST): limits tumour growth by inhibiting c‑KIT and PDGFR activity.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, often in the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools. - Muscle cramps: occasional skeletal muscle discomfort.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Cardiotoxicity: congestive heart failure or reduced left‑ventricular function. - Severe neutropenia: marked decrease in neutrophil count. - Hemorrhage: bleeding events, including gastrointestinal bleeding. - Hypersensitivity reactions: rash, fever, or anaphylaxis.

When prescribing Imatinib, clinicians should consider several safety precautions.

- Baseline liver function: assess hepatic enzymes before initiating therapy. - Cardiac assessment: evaluate left‑ventricular ejection fraction in patients with cardiac history. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce Imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase Imatinib levels and risk of adverse effects. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly reduce bioavailability; separate dosing by at least 2 hours. - Warfarin: enhanced anticoagulant effect; monitor INR closely. - CYP2C8 substrates (e.g., repaglinide): possible increased exposure; adjust dose as needed.